TY - JOUR T1 - Impact and cost-effectiveness of formal gastroenterology outpatient referral Clinical Assessment Service JF - Frontline Gastroenterology JO - Frontline Gastroenterol DO - 10.1136/flgastro-2017-100853 SP - flgastro-2017-100853 AU - Stavroula Pelitari AU - Charlotte Hathaway AU - Dean Gritton AU - Andrea Smith AU - David Bush AU - Shyam Menon AU - Brian McKaig Y1 - 2017/09/23 UR - http://fg.bmj.com/content/early/2017/09/23/flgastro-2017-100853.abstract N2 - Objective The aim was to assess the financial and operational impact of our new gastroenterology referral pathway model on our services.Design An electronic ‘Clinical Assessment Service’ (CAS) proforma and an information platform were developed, and all data were analysed retrospectively.Setting Royal Wolverhampton NHS Trust.Patients 14 245 general practitioner (GP) referrals were received during January 2014–December 2016 with 9773 of them being triaged via our CAS.Main outcome measures We looked into patients’ clinical outcome along with departmental performance and finances.Results A new outpatient appointment was offered to 60.1% (n=5873) of the CAS referred patients. Endoscopic or radiological investigations were requested for 29.2% (n=2854) of patients prior to deciding on further management plan. Out of those, 27% (n=765) went on to receive another gastroenterology (GI) clinic appointment. The remaining 21.3% (n=2089) of the CAS patients were discharged back to their GP following initial investigations. 5.5% (n=538) were discharged back to primary care with a letter of advice, whereas 5.2% (n=509) were deemed inappropriate for GI clinic and were redirected to other specialists. Overall, 32% (n=3127) of patients were managed without a face to face consultation in the GI clinic. This corresponds to 3136 less outpatient appointments with estimated reduced expenditure by the Clinical Commissioning Group (CCG) of £481K. The 18-week performance and waiting times remained stable despite the increasing referral population. The DNA rate dropped from 14% pre to 8.5%.Conclusions Our clinical assessment model has, in addition to the clinical benefits, a considerable positive financial impact to the health economy. ER -